Quince Therapeutics, Inc.·4

Jan 8, 7:30 PM ET

Lamond David 4

4 · Quince Therapeutics, Inc. · Filed Jan 8, 2025

Insider Transaction Report

Form 4
Period: 2025-01-02
Lamond David
Director
Transactions
  • Award

    Director Stock Option (right to buy)

    2025-01-02+47,58747,587 total
    Exercise: $1.88Exp: 2035-01-02Common Stock (47,587 underlying)
Footnotes (1)
  • [F1]The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the Issuer's Outside Director Compensation Policy.

Documents

1 file
  • 4
    form4-01092025_120154.xmlPrimary